Additionally, cytokine therapies such as the administration of recombinant IL‐7 and low dose of IL‐2 could be beneficial in restoring T‐cell counts and expanding Tregs in COVID‐19 patients, especially in those with severe disease to control excessive inflammatory response. The gene discussed is IL2; the disease is COVID-19.